Most cited papers from Arvinas (United States)

Arvinas (United States)

What are the most cited papers from Arvinas (United States)?

The most cited paper from Arvinas (United States) is "PROTAC targeted protein degraders: the past is prologue" (Miklós Békés, David R. Langley, Craig M. Crews, 2022), with 3,294 citations. Next come "Catalytic in vivo protein knockdown by small-molecule PROTACs" (1,365) and "Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4" (1,162).

Published TypeFieldAccessCitations

Showing 50 of 59 papers. Every paper with more than 15 citations is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	PROTAC targeted protein degraders: the past is prologue Miklós Békés, David R. Langley, Craig M. Crews · Nature Reviews Drug Discovery ReviewOpen access	18 Jan 2022	3,294
2	Catalytic in vivo protein knockdown by small-molecule PROTACs Daniel P. Bondeson et al. · Nature Chemical Biology Open access	10 Jun 2015	1,365
3	Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4 Jing Lü, Yimin Qian, Martha Altieri et al. · Chemistry & Biology Open access	Jun 2015	1,162
4	Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead Daniel P. Bondeson, Blake E. Smith, George M. Burslem et al. · Cell chemical biology Open access	9 Nov 2017	938
5	PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer Kanak Raina, Jing Lü, Yimin Qian et al. · Proceedings of the National Academy of Sciences Open access	6 Jun 2016	855
6	The Advantages of Targeted Protein Degradation Over Inhibition: An RTK Case Study George M. Burslem, Blake E. Smith, Ashton C. Lai et al. · Cell chemical biology Open access	9 Nov 2017	699
7	Protein degraders enter the clinic — a new approach to cancer therapy Deborah Chirnomas, Keith R. Hornberger, Craig M. Crews · Nature Reviews Clinical Oncology ReviewOpen access	13 Feb 2023	637
8	Targeted protein degradation by PROTACs Taavi K. Neklesa, James D. Winkler, Craig M. Crews · Pharmacology & Therapeutics	14 Feb 2017	589
9	Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase Blake E. Smith, Stephen L. Wang, Saul Jaime‐Figueroa et al. · Nature Communications Open access	4 Jan 2019	532
10	Androgen receptor degradation by the proteolysis-targeting chimera ARCC-4 outperforms enzalutamide in cellular models of prostate cancer drug resistance Jemilat Salami, Shanique B. Alabi, Ryan R. Willard et al. · Communications Biology Open access	27 Jul 2018	353
11	MDM2-Recruiting PROTAC Offers Superior, Synergistic Antiproliferative Activity via Simultaneous Degradation of BRD4 and Stabilization of p53 John F. Hines, Schan Lartigue, Hanqing Dong et al. · Cancer Research Open access	Nov 2018	348
12	Identification and Characterization of Von Hippel-Lindau-Recruiting Proteolysis Targeting Chimeras (PROTACs) of TANK-Binding Kinase 1 Andrew P. A. Crew, Kanak Raina, Hanqing Dong et al. · Journal of Medicinal Chemistry Open access	10 Jul 2017	256
13	Oral Estrogen Receptor PROTAC Vepdegestrant (ARV-471) Is Highly Efficacious as Monotherapy and in Combination with CDK4/6 or PI3K/mTOR Pathway Inhibitors in Preclinical ER+ Breast Cancer Models Sheryl M. Gough et al. · Clinical Cancer Research Open access	31 May 2024	191
14	Novel BET protein proteolysis-targeting chimera exerts superior lethal activity than bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm secondary (s) AML cells Dyana T. Saenz et al. · Leukemia Open access	2 Jan 2017	190
15	BET protein proteolysis targeting chimera (PROTAC) exerts potent lethal activity against mantle cell lymphoma cells Baohua Sun, Warren C. Fiskus, Yimin Qian et al. · Leukemia Open access	30 Jun 2017	182
16	Enhancing Antiproliferative Activity and Selectivity of a FLT-3 Inhibitor by Proteolysis Targeting Chimera Conversion George M. Burslem, Jayoung Song, Xin Chen et al. · Journal of the American Chemical Society	14 Nov 2018	178
17	Physicochemical Property Determinants of Oral Absorption for PROTAC Protein Degraders Keith R. Hornberger, Erika M. V. Araujo · Journal of Medicinal Chemistry Open access	6 Jun 2023	173
18	Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast Cancer Mario Campone et al. · New England Journal of Medicine	31 May 2025	150
19	Selective PROTAC-mediated degradation of SMARCA2 is efficacious in SMARCA4 mutant cancers Jennifer L. Cantley et al. · Nature Communications Open access	10 Nov 2022	138
20	Activity profiling and structures of inhibitor-bound SARS-CoV-2-PLpro protease provides a framework for anti-COVID-19 drug design Wioletta Rut, Zongyang Lv, Mikolaj Zmudzinski et al. · bioRxiv (Cold Spring Harbor Laboratory) PreprintOpen access	29 Apr 2020	123
21	Targeted protein knockdown using small molecule degraders Kanak Raina, Craig M. Crews · Current Opinion in Chemical Biology ReviewOpen access	10 Jun 2017	112
22	Molecular Characterization of a Neutralizing Domain of the Japanese Encephalitis Virus Structural Glycoprotein Peter W. Mason, Joel M. Dalrymple, Mary Kay Gentry et al. · Journal of General Virology	Aug 1989	109
23	THE ISOLATION OF A BLUETONGUE VIRUS FROM CULICOIDES COLLECTED IN THE NORTHERN TERRITORY OF AUSTRALIA T. D. St. George, H. A. Standfast, D. H. Cybinski et al. · Australian Veterinary Journal	Mar 1978	105
24	VERITAC-2: a Phase III study of vepdegestrant, a PROTAC ER degrader, versus fulvestrant in ER+/HER2- advanced breast cancer Erika Paige Hamilton, Cynthia X. Ma, Michelino De Laurentiis et al. · Future Oncology Open access	29 Jul 2024	104
25	RUNX1-targeted therapy for AML expressing somatic or germline mutation in RUNX1 Christopher Peter Mill, Warren C. Fiskus, Courtney Denton Dinardo et al. · Blood Open access	25 Apr 2019	100
26	Targeting Nuclear Receptors with PROTAC degraders John J. Flanagan, Taavi K. Neklesa · Molecular and Cellular Endocrinology	21 May 2019	96
27	Safety and efficacy of eculizumab for the prevention of antibody-mediated rejection after deceased-donor kidney transplantation in patients with preformed donor-specific antibodies Denis Glotz, Graeme R. Russ, Lionel P. E. Rostaing et al. · American Journal of Transplantation Open access	23 Apr 2019	93
28	Preclinical Evaluation of Bavdegalutamide (ARV-110), a Novel PROteolysis TArgeting Chimera Androgen Receptor Degrader Lawrence B. Snyder, Taavi K. Neklesa, Ryan R. Willard et al. · Molecular Cancer Therapeutics Open access	13 Dec 2024	87
29	A first-in-human phase I study to evaluate the MEK1/2 inhibitor, cobimetinib, administered daily in patients with advanced solid tumors Lee S. Rosen, Patricia Mucci LoRusso, Wen Wee Ma et al. · Investigational New Drugs Open access	16 Jul 2016	85
30	A MYC and RAS co-activation signature in localized prostate cancer drives bone metastasis and castration resistance Juan Martín Arriaga et al. · Nature Cancer Open access	19 Oct 2020	83
31	Protein targeting chimeric molecules specific for bromodomain and extra-terminal motif family proteins are active against pre-clinical models of multiple myeloma Xiaohui Zhang et al. · Leukemia Open access	26 Mar 2018	83
32	Current directions in tau research: Highlights from Tau 2020 Claire E. Sexton et al. · Alzheimer s & Dementia Open access	28 Sep 2021	79
33	BETP degradation simultaneously targets acute myelogenous leukemic stem cells and the microenvironment Sujan Piya, Hong Hua Mu, Seemana Bhattacharya et al. · Journal of Clinical Investigation Open access	21 Feb 2019	73
34	Proteolysis-Targeting Chimeras: Harnessing the Ubiquitin-Proteasome System to Induce Degradation of Specific Target Proteins Kevin G. Coleman, Craig M. Crews · Annual Review of Cancer Biology Review	30 Oct 2017	68
35	Oral Migalastat HCl Leads to Greater Systemic Exposure and Tissue Levels of Active α-Galactosidase A in Fabry Patients when Co-Administered with Infused Agalsidase David G. Warnock, Daniel Georges Bichet, Myrl D. Holida et al. · PLoS ONE Open access	7 Aug 2015	63
36	Co-opting the E3 ligase KLHDC2 for targeted protein degradation by small molecules Christopher M. Hickey, Katherine Marie Digianantonio, Kurt Zimmermann et al. · Nature Structural & Molecular Biology	4 Jan 2024	62
37	Efficient Synthesis of Immunomodulatory Drug Analogues Enables Exploration of Structure–Degradation Relationships George M. Burslem, Philipp Ottis, Saul Jaime‐Figueroa et al. · ChemMedChem Open access	5 Jun 2018	58
38	A highly accurate metadynamics-based Dissociation Free Energy method to calculate protein–protein and protein–ligand binding potencies Jing Wang, Alexey V. Ishchenko, Wei Zhang et al. · Scientific Reports Open access	7 Feb 2022	54
39	Duvoglustat HCl Increases Systemic and Tissue Exposure of Active Acid α-Glucosidase in Pompe Patients Co-administered with Alglucosidase α Priya Sunil Kishnani et al. · Molecular Therapy Open access	22 Mar 2017	46
40	Targeting nuclear β-catenin as therapy for post-myeloproliferative neoplasm secondary AML Dyana T. Saenz et al. · Leukemia Open access	21 Dec 2018	42
41	Arbovirus infections in Sarawak: The isolation of Kunjin virus from mosquitoes of theCulex pseudovishnuigroup E. T. W. Bowen, David I. H. Simpson, G. S. Platt et al. · Annals of Tropical Medicine and Parasitology	Sep 1970	41
42	New therapies on the horizon: Targeted protein degradation in neuroscience James A Gregory, Christopher M. Hickey, Juan D. Chavez et al. · Cell chemical biology Open access	Sep 2024	38
43	SEROLOGICAL RELATION BETWEEN RIFT VALLEY FEVER VIRUS AND VIRUSES OF PHLEBOTOMUS FEVER SEROGROUP RobertE. Shope, ClarenceJ. Peters, J.S. Walker · The Lancet	Apr 1980	35
44	PROTACs Targeting BRM (SMARCA2) Afford Selective In Vivo Degradation over BRG1 (SMARCA4) and Are Active in BRG1 Mutant Xenograft Tumor Models Michael Y. Berlin et al. · Journal of Medicinal Chemistry Open access	5 Jan 2024	34
45	Integration of Affinity Selection–Mass Spectrometry and Functional Cell-Based Assays to Rapidly Triage Druggable Target Space within the NF-κB Pathway Victoria D. Kutilek et al. · SLAS DISCOVERY Open access	11 Mar 2016	33
46	Reversion analysis reveals the in vivo immunogenicity of a poorly MHC I-binding cancer neoepitope Hakimeh Ebrahimi-Nik, Marmar R. Moussa, Ryan P. Englander et al. · Nature Communications Open access	5 Nov 2021	32
47	Highly Enantioselective Rhodium-Catalyzed Cross-Addition of Silylacetylenes to Cyclohexadienone-Tethered Internal Alkynes Chang-Lin Duan, Yun‐Xuan Tan, Junli Zhang et al. · Organic Letters	Mar 2019	32
48	Immunopathologic Aspects of Infection with Lagos Bat Virus of the Rabies Serogroup Gregory H. Tignor, Robert E. Shope, Richard K. Gershon et al. · The Journal of Immunology	1974	30
49	MONOCLONAL ANTIBODIES TO IDENTIFY ZINGA VIRUS AS RIFT VALLEY FEVER VIRUS James M. Meegan, J.P. Digoutte, Clarence J. Peters et al. · The Lancet	Mar 1983	30
50	Development of Liposome Systems for Enhancing the PK Properties of Bivalent PROTACs Ponien Kou, Elizabeth S. Levy, An D. Nguyen et al. · Pharmaceutics Open access	8 Aug 2023	25

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.